Showing results (401-410 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|December 1, 2017
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individualsAkil Jackson, Laura Else, Christopher Higgs, et al.
HIV Clinical Trials|November 29, 2017
Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary teamE Molas, S Luque, A Retamero, et al.
HIV Clinical Trials|February 16, 2018
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practiceJuan A Pineda, Antonio Rivero-Juárez, Ignacio de Los Santos, et al.
HIV Clinical Trials|February 24, 2018
New design, development, and optimization of an in-house quantitative TaqMan Real-time PCR assay for HIV-1 viral load measurementHassan Noorbazargan, Seyed Alireza Nadji, Siamak Mirab Samiee, et al.
HIV Clinical Trials|February 6, 2018
Short-term folinic acid supplementation and aerobic exercise improve vascular reactivity in HIV-infected individualsShana S Grigoletti, Jorge P Ribeiro, Eduardo Sprinz, et al.
HIV Clinical Trials|December 8, 2018
Natural control of HIV infection in young women in South Africa: HPTN 068Mariya V Sivay, Jessica M Fogel, Jing Wang, et al.
HIV Clinical Trials|April 14, 2009
Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serumChantelle Bennetto-Hood, Yvonne J Bryson, Alice Stek, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
HIV Clinical Trials|July 28, 2009
Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patientsTsan Lee, Marina Núñez
HIV Clinical Trials|August 28, 2007
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3Anita Rachlis, Bonaventura Clotet, John Baxter, et al.
Pageof 68